DXI Capital Corp. Announces Share Consolidation and Name Change Ahead of Reverse Takeover.

DXI Capital Corp. will consolidate its issued and outstanding common shares on a 4:67 basis, reducing its 11,966,024 shares to 2,562,318. The consolidation is in advance of a proposed reverse takeover by V.V.T. Med Ltd. and Exiteam Acquisition Corp. The DXI Shares will be halted pending closing of the proposed transaction and will change its name to "VVT Med Inc." with a new trading symbol of "VVTM".

Toronto, Ontario—DXI Capital Corp. (TSXV: DXI.H) has announced that it will consolidate its issued and outstanding common shares on a 4:67 basis, reducing the total number of shares from 11,966,024 to 2,562,318. This consolidation is scheduled to take effect on July 18, 2025 [1].

The consolidation is part of the company's strategy to facilitate a proposed reverse takeover by V.V.T. Med Ltd. (VVT) and Exiteam Acquisition Corp. (EAC). The reverse takeover is subject to approval by the TSX Venture Exchange (TSXV) and is expected to close on July 21, 2025, with trading of the Resulting Issuer's common shares commencing shortly thereafter [1].

As part of the reverse takeover, DXI will change its name to "VVT Med Inc." and will adopt the new trading symbol "VVTM". The new CUSIP number will be 91841T108, and the new ISIN number will be CA91841T1084 for the post-consolidation shares [1].

The consolidation will be carried out without the issuance of fractional shares. Shareholders will receive post-consolidation shares in exchange for their pre-consolidation shares, with no action required for those holding shares in brokerage accounts or book-entry form [1].

In conjunction with the proposed transaction, EAC is conducting a non-brokered private placement to raise minimum gross proceeds of $4,500,000. As of July 16, 2025, EAC has issued 6,955,498 subscription receipts, generating total gross proceeds of approximately $3,895,078 [1].

VVT is also conducting a non-brokered private placement to raise minimum gross proceeds of $4,500,000, inclusive of the gross proceeds derived to date from the Concurrent EAC Financing. As of July 15, 2025, VVT has closed its financing and issued convertible debentures with a face value of approximately $922,477 for gross proceeds of $781,761 [1].

The aggregate gross proceeds of the EAC Concurrent Financing and VVT Concurrent Financing are approximately $4,676,839. The principal amount and interest of the Convertible Debentures may be converted into units of VVT at a price of $0.56 per unit, with each unit consisting of one ordinary share of VVT and one warrant to acquire a VVT share [1].

The proposed transaction is subject to various conditions, including the receipt of all requisite third-party approvals, authorizations, and consents, and the satisfaction of conditions set out in the definitive agreement between the parties [1].

Investors are cautioned that the information released or received regarding the proposed transaction may not be accurate or complete and should not be relied upon. Trading in the securities of DXI should be considered highly speculative, and shares are currently halted from trading on the TSXV until after the completion of the proposed transaction [1].

References:
[1] https://www.streetinsider.com/Newsfile/DXI+Capital+Corp.+Effects+Share+Consolidation+and+Name+Change+in+Advance+of+Closing+Proposed+Reverse+Takeover+by+V.V.T.+Med+Ltd.+and+Exiteam+Acquisition+Corp./25057643.html